- $513.89m
- $417.99m
- $85.23m
Brief: Delcath Systems Appoints Vojislav Vukovic As Chief Medical Officer
Brief: Delcath Systems Inc Files For Resale Of Up To Up To 19.51 Million Shares Of Common Stock- SEC Filing
Brief: Delcath Systems Reports Preliminary First Quarter 2023 Financial Results
Delcath Systems Inc expected to post a loss of 61 cents a share - Earnings Preview
Delcath Systems Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Delcath Systems Announces Resumption Of Interest-Only Period For Company's Debt Facility
Delcath Systems rises on financing, NDA approval
Brief: Delcath Systems Reports Q4 Loss Per Share Of $0.86
Brief: Delcath Systems Announces FDA Acceptance Of NDA Resubmission Of Hepzato Kit
Brief: Delcath Systems Announces Up To $85 Million Financing
Delcath Systems Inc expected to post a loss of 76 cents a share - Earnings Preview
Brief: Delcath Announces Rotation Of The Board Of Directors Chairmanship
Brief: Delcath Systems Announces New Drug Application Resubmission For Hepzato Kit
Brief: Delcath Systems Regains Compliance With Nasdaq Market Value Standard
Brief: Delcath Systems Announces Updated Results From CHOPIN Phase 1b Trial Published In Cardiovascular And Interventional Radiology
Brief: Delcath Systems Inc Expects To Submit NDA To FDA During Q1 2023 For Hepzato Kit
Brief: Delcath Systems Inc Files For Resale Of Up To 2.14 Mln Shares - SEC Filing
U.S. RESEARCH ROUNDUP-Beauty Health, Bioventus, Cabot
Brief: Delcath Systems Reports Third Quarter Results